The research team set out to answer a deceptively simple question: when prostate cancer cells stop responding to enzalutamide, what has actually changed inside them? Resistance is often described in terms of genetic mutations in the androgen receptor or amplification of the receptor gene itself, but these alterations explain only a fraction of clinical cases. Increasingly, cancer biologists have recognized that drug-tolerant cells frequently survive by adjusting their metabolism, the network of chemical reactions that converts nutrients into energy, building blocks and signaling molecules. Because metabolic rewiring is a physical requirement for survival rather than an optional accessory, it may represent a more universal and more druggable hallmark of resistance than any single mutation.

To capture that rewiring comprehensively, the investigators applied a multi-omic pipeline to paired models of enzalutamide-sensitive and enzalutamide-resistant prostate cancer cells. Transcriptomic sequencing revealed which genes were switched on or off; proteomic mass spectrometry quantified the enzymes actually present in the cells; and metabolomic profiling measured the small molecules, sugars, amino acids and lipids that flow through the metabolic network. The power of this approach lies in its convergence. A change in a single data type can be misleading, but when altered messenger RNA, altered protein and altered metabolite levels all point to the same pathway, the evidence becomes difficult to dismiss.

The analysis converged on several interconnected metabolic shifts. Resistant cells displayed a marked reorganization of lipid metabolism, upregulating pathways for fatty acid synthesis and elongation while also altering cholesterol handling. This makes biological sense for prostate cancer in particular, because the androgen receptor does more than respond to testosterone; it also regulates genes involved in lipid acquisition and synthesis, and membrane lipid composition influences receptor signaling at the cell surface. By boosting de novo lipogenesis, resistant cells appear to buffer themselves against the loss of androgen-driven lipid programs that enzalutamide imposes, effectively rebuilding a supply line the drug was designed to cut.

Energy metabolism showed equally telling changes. Profiling of central carbon metabolism indicated that resistant cells leaned more heavily on glycolysis and on glutamine-fueled anaplerosis, the process by which the amino acid glutamine tops up the tricarboxylic acid cycle with carbon. Mitochondrial oxidative phosphorylation was also reconfigured, with altered expression of electron transport chain components suggesting a shift in how resistant cells balance ATP production against the generation of biosynthetic precursors. These are not idle adjustments. Rapidly dividing tumor cells must simultaneously produce energy, reduce cellular building blocks and maintain antioxidant defenses, and the observed pattern is characteristic of cells that have traded metabolic efficiency for metabolic flexibility.

Crucially, the study did not stop at description. The researchers tested whether the metabolic alterations they detected could be exploited therapeutically. Inhibiting key enzymes in the upregulated lipid synthesis pathway reduced the viability of enzalutamide-resistant cells more severely than that of their drug-sensitive counterparts, indicating a genuine dependence rather than incidental correlation. Similar experiments targeting glutamine metabolism and mitochondrial respiration produced the same pattern of selective vulnerability. When metabolic inhibitors were combined with continued enzalutamide treatment, the effect was additive, and in some settings synergistic, meaning that the resistant cells could be resensitized to the drug they had learned to ignore.

The concept underlying these results is known as collateral vulnerability. When cancer cells evolve resistance to one pressure, the evolutionary path they take often creates new dependencies that did not exist before. A cell that ramps up fatty acid synthesis to survive androgen receptor blockade, for example, becomes exquisitely sensitive to inhibitors of that synthesis pathway. Because these dependencies are consequences of the resistance program itself, they are less likely to be bypassed by further tumor evolution without a significant fitness cost. This is the same logic that has made synthetic lethal strategies, such as PARP inhibition in DNA repair-deficient tumors, one of the most productive ideas in modern oncology, now extended into the metabolic arena.

The findings carry practical implications for the clinic. Enzalutamide resistance currently marks a transition point at which patients move toward chemotherapy, androgen biosynthesis inhibitors or, for those with suitable tumor biology, radioligand therapy. If metabolic vulnerabilities of the kind identified here can be confirmed in patient-derived models and ultimately in clinical trials, metabolic inhibitors could be layered onto existing regimens at the first sign of rising prostate-specific antigen during enzalutamide treatment, potentially delaying or preventing overt resistance. The study also raises the possibility of using metabolic imaging or circulating metabolite profiles as biomarkers, allowing clinicians to detect the metabolic shift before the tumor has fully escaped hormonal control.

Several caveats temper the enthusiasm. Cell line models, even well-characterized ones, capture only part of the complexity of human tumors, which contain stromal cells, immune infiltrates, variable oxygen and nutrient availability and extensive intratumoral heterogeneity. Metabolic phenotypes are notoriously context-dependent, shaped by the culture conditions in which cells are grown and by the specific evolutionary path each resistant line has taken. The authors’ use of multiple paired models and convergent multi-omic evidence strengthens their conclusions, but translating these dependencies into patients will require validation in organoids, xenografts and ultimately biopsy material from men whose disease has progressed on enzalutamide. Dose-limiting toxicities of metabolic inhibitors, particularly those affecting normal tissues with high metabolic flux, will also need careful management.

Nevertheless, the study represents a meaningful step toward a more complete picture of how prostate cancer defeats one of its most important therapies. By treating metabolism not as background housekeeping but as a central player in drug resistance, and by interrogating that metabolism with layers of molecular data rather than single measurements, the work provides both a mechanistic map and a practical target list. For the growing population of men living with castration-resistant prostate cancer, the hope is that the very adaptations tumors use to survive enzalutamide will become the handles by which the next generation of treatments pulls them back into vulnerability.

Subject of Research: Metabolic rewiring in enzalutamide-resistant prostate cancer identified through integrated transcriptomic, proteomic and metabolomic profiling

Article Title: Multi-omic profiling reveals metabolic vulnerabilities in enzalutamide resistant prostate cancer

Article References: Lee, O., Fidelito, G., Zhao, Q., Liu, B., Choi, H., Taylor, R. A., & Watt, M. J. (2026). Multi-omic profiling reveals metabolic vulnerabilities in enzalutamide resistant prostate cancer. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03332-3

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03332-3

Keywords: prostate cancer, enzalutamide, drug resistance, multi-omics, metabolism, lipid metabolism, glutamine, androgen receptor, oxidative phosphorylation, collateral vulnerability, cancer therapeutics, Cell Death Discovery

Tiefenbacher, A., Gudenus, M., Valcanover, D. et al. Adipose triglyceride lipase driven lipolysis as a targetable metabolic vulnerability in prostate cancer with intrinsic metabolic inflexibility.
Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03545-4

23 July 2026

Prostate cancer metastasis remains one of the greatest clinical challenges, significantly escalating mortality associated with this common malignancy. While previous research has extensively investigated genetic mutations and signaling pathways driving cancer spread, this study introduces a fresh perspective by linking metabolic regulation and epigenetic modifications to metastatic behavior. RBM14, traditionally recognized for its role in RNA metabolism, has now emerged as a critical mediator stabilizing HK2 mRNA, thereby sustaining elevated glycolytic activity. This metabolic reprogramming provides metastatic cancer cells with a rapid energy supply and biosynthetic precursors essential for invasion and survival in distant tissues.

The molecular architecture of this pathway reveals that RBM14 binds directly to HK2 mRNA, protecting it from degradation. Hexokinase 2 (HK2) is a key enzyme catalyzing the initial step of glycolysis by phosphorylating glucose to glucose-6-phosphate, effectively committing glucose to cellular energy metabolism. Enhanced HK2 expression driven by RBM14 ensures an abundant flux through glycolysis, a hallmark of aggressive cancer metabolism often termed the “Warburg effect”. However, the authors uniquely emphasize that this metabolic shift is not merely a consequence but an active driver of metastatic progression thanks to its downstream effects on chromatin modifications.

Intriguingly, the robust glycolytic activity fueled by RBM14-mediated HK2 stabilization leads to elevated intracellular lactate levels. Lactate, traditionally regarded as a metabolic byproduct, has recently been recognized for its signaling functions and involvement in epigenetic regulation. The study highlights H3K18 lactylation, a histone modification where lactate moieties are appended to lysine 18 on histone H3, as a direct epigenetic mark induced by this metabolic rewiring. This histone lactylation event significantly reprograms gene expression profiles to favor metastatic phenotypes, including enhanced motility, invasiveness, and resistance to apoptosis.

From a biochemical perspective, this research integrates the fields of RNA biology, metabolism, and epigenetics into a comprehensive framework explaining prostate cancer metastasis. The use of advanced RNA immunoprecipitation and next-generation sequencing analyses validated the binding affinity of RBM14 for HK2 transcripts and demonstrated the consequent augmentation in glycolytic gene networks. Furthermore, chromatin immunoprecipitation coupled with mass spectrometry provided compelling evidence for the presence and functional significance of H3K18 lactylation in tumor samples exhibiting high RBM14 expression.

In vitro and in vivo experiments further consolidated the conceptual model, where knockdown of RBM14 led to the destabilization of HK2 mRNA, a marked decrease in glycolysis rates, and subsequent reduction in H3K18 lactylation. This intervention translated into diminished metastatic potential in prostate cancer cell lines and mouse xenograft models, underscoring the therapeutic promise of targeting RBM14 or its downstream metabolic and epigenetic pathways. Notably, the study also explored small molecule inhibitors capable of disrupting the RBM14-HK2 interaction, revealing preliminary efficacy in curtailing metastatic spread.

This body of work not only highlights RBM14 as a molecular linchpin in prostate cancer metastasis but also challenges the traditional compartmentalization of metabolic and epigenetic regulation as independent axes of cancer biology. The interplay elucidated here points to a highly integrated regulatory network, suggesting that cancer cells exploit metabolic intermediates not solely for energy but as epigenetic modulators to tightly control gene expression in favor of malignancy. Moreover, lactylation emerges as a key epigenetic marker with potential diagnostic and prognostic implications within the prostate cancer continuum.

The clinical implications beckon a new era of metabolic and epigenetic targeted therapy. Given the poor prognosis associated with metastatic prostate cancer, strategies inhibiting RBM14-mediated HK2 mRNA stabilization or disrupting lactate-driven histone modifications could provide transformative benefits. Early-phase clinical trials targeting similar metabolic pathways in other cancers lend credence to the translational feasibility of this approach. Future research might focus on pharmacologic agents specifically designed to modulate lactylation or RBM14 activity, potentially revolutionizing treatment paradigms for metastatic prostate cancer.

Beyond prostate cancer, these findings may have broader impact across oncology, as metabolic-epigenetic cross-talk likely underlies metastatic behaviors in diverse tumor types. RBM14’s role as an RNA-binding protein stabilizer could be a general mechanism leveraged by cancer cells to sustain metabolic adaptations critical for dissemination. The identification of lactylation opens avenues for discovering other lactate-dependent epigenetic marks influencing chromatin state and cancer evolution. This work thus provides a conceptual template for exploring metabolic regulation of chromatin in cancer progression.

Scientifically, the revelation of H3K18 lactylation as a pro-metastatic epigenetic modification invites deeper inquiries into the enzymatic machinery responsible for adding and removing these lactyl groups. Decoding the “writers,” “readers,” and “erasers” of histone lactylation will enrich understanding of how metabolic flux integrates with gene regulation and how such mechanisms are exploited in cancer. Additionally, the crosstalk between lactylation and other histone marks, such as acetylation and methylation, may reveal complex layers of epigenetic control fine-tuning cancer cell identity and plasticity.

On a methodological note, this study exemplifies the power of combining multi-omics approaches, including transcriptomics, metabolomics, and epigenomics, to untangle the multidimensional regulatory networks driving cancer aggressiveness. The sophisticated experimental design involving genetic, biochemical, and pharmacological manipulations allowed for a nuanced dissection of cause-and-effect relationships in the RBM14-HK2-lactylation axis. This comprehensive approach sets a new standard for dissecting molecular pathways underpinning metastasis and highlights the importance of interdisciplinary collaboration.

In sum, Liu, Guo, You, and colleagues’ discovery of RBM14’s role in stabilizing HK2 mRNA to activate glycolysis and induce H3K18 histone lactylation unveils a vital metabolic-epigenetic circuit fueling prostate cancer metastasis. This landmark study not only advances fundamental understanding of cancer biology but also identifies promising therapeutic targets to impede the spread of a devastating disease. As the oncology community seeks innovative strategies to combat metastasis, targeting the metabolic-epigenetic interface illuminated here represents a compelling frontier with enormous translational potential.

The emerging paradigm underscored by this research suggests that future oncologic therapies may need to simultaneously address metabolic vulnerabilities and epigenetic dynamics to effectively halt the complex process of metastasis. By illuminating how RBM14 orchestrates glycolysis and epigenetic remodeling through HK2 mRNA stabilization and H3K18 lactylation, the study paves the way for novel biomarkers and combinatorial treatment strategies aiming at metabolic and epigenetic aberrations. This comprehensive insight fosters hope for markedly improved outcomes for patients suffering from advanced prostate cancer.

In conclusion, this study fundamentally reshapes the understanding of how metabolic reprogramming and histone modifications intersect to drive prostate cancer metastasis. The identification of RBM14 as a critical stabilizer of HK2 mRNA and the elucidation of H3K18 lactylation as a pivotal epigenetic modification open profound new vistas for cancer research and therapeutics. As we advance toward precision medicine, integrating metabolic and epigenetic targeting holds the promise of unlocking more effective therapies to arrest cancer progression and improve patient survival.

Subject of Research: Role of RBM14 in prostate cancer metastasis via HK2 mRNA stabilization and activation of glycolysis and epigenetic modification (H3K18 lactylation).

Article Title: RBM14 drives prostate cancer metastasis via stabilizing HK2 mRNA to activate glycolysis and H3K18 lactylation.

Article References: Liu, Z., Guo, H., You, Z. et al. RBM14 drives prostate cancer metastasis via stabilizing HK2 mRNA to activate glycolysis and H3K18 lactylation. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03131-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03131-w